Exelixis (EXEL) News Today

Exelixis, Inc. (NASDAQ:EXEL - Free Report) - Analysts at Leerink Partnrs issued their FY2024 earnings estimates for shares of Exelixis in a research note issued to investors on Wednesday, July 24th. Leerink Partnrs analyst A. Berens forecasts that the biotechnology company will post earnings of $

Exelixis, Inc. (NASDAQ:EXEL - Free Report) - Leerink Partnrs increased their Q2 2024 earnings estimates for shares of Exelixis in a note issued to investors on Wednesday, July 24th. Leerink Partnrs analyst A. Berens now forecasts that the biotechnology company will earn $0.32 per share for the qu

Vanguard Group Inc. reduced its holdings in shares of Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 2.7% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 30,819,783 shares of the biotechnology company's stock after

Seven Eight Capital LP grew its holdings in shares of Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 234.2% during the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 75,661 shares of the biotechnology company's stock after purchasing an additional 53,024 sha

Acadian Asset Management LLC lowered its stake in Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 31.2% during the first quarter, according to the company in its most recent filing with the SEC. The fund owned 1,218,514 shares of the biotechnology company's stock after selling 553,663 shares during t

Intech Investment Management LLC lifted its holdings in shares of Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 155.8% during the 1st quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 100,039 shares of the biotechnology company's stock after acquiring

Sei Investments Co. boosted its holdings in shares of Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 81.9% in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 505,319 shares of the biotechnology company's stock after buying an additio

Exelixis, Inc. (NASDAQ:EXEL - Get Free Report) was the target of a significant decline in short interest during the month of June. As of June 30th, there was short interest totalling 9,190,000 shares, a decline of 7.5% from the June 15th total of 9,940,000 shares. Approximately 3.2% of the company's stock are short sold. Based on an average daily trading volume, of 1,890,000 shares, the short-interest ratio is presently 4.9 days.

Susquehanna Fundamental Investments LLC bought a new position in Exelixis, Inc. (NASDAQ:EXEL - Free Report) in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 459,596 shares of the biotechnology company's stock, valued at app

Exelixis, Inc. (NASDAQ:EXEL - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the seventeen research firms that are currently covering the stock, Marketbeat reports. Seven investment analysts have rated the stock with a hold rating and ten have assigned a buy rating to

LSV Asset Management lifted its stake in shares of Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 1,651.4% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 2,774,707 shares of the biotechnology company's stock after a

StockNews.com upgraded shares of Exelixis from a "buy" rating to a "strong-buy" rating in a research note on Saturday.

GSA Capital Partners LLP acquired a new position in Exelixis, Inc. (NASDAQ:EXEL - Free Report) during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 53,981 shares of the biotechnology company'

StockNews.com downgraded shares of Exelixis from a "strong-buy" rating to a "buy" rating in a report on Friday.

Allspring Global Investments Holdings LLC trimmed its holdings in shares of Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 7.3% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,278,910 shares of the biotech

StockNews.com upgraded shares of Exelixis from a "buy" rating to a "strong-buy" rating in a research report on Thursday.

Vanguard Group Inc. lowered its stake in Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 1.2% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 31,671,090 shares of the biotechnology company's stock after selling 400,130 s

Los Angeles Capital Management LLC lifted its position in Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 948.3% during the 1st quarter, according to the company in its most recent filing with the SEC. The fund owned 2,454,277 shares of the biotechnology company's stock after purchasing an additional

Shares of Exelixis, Inc. (NASDAQ:EXEL - Get Free Report) have received a consensus rating of "Moderate Buy" from the seventeen research firms that are presently covering the company, MarketBeat.com reports. Seven research analysts have rated the stock with a hold recommendation and ten have given a

Nomura Holdings Inc. lifted its holdings in Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 234.4% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 194,968 shares of the biotechnology company's stock after purchasing an additional 136,668 shares dur

Nomura Holdings Inc. raised its position in shares of Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 234.4% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 194,968 shares of the biotechnology company'

True Wealth Design LLC bought a new position in Exelixis, Inc. (NASDAQ:EXEL - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 34,516 shares of the biotechnology company's stock, valued at

Bellevue Group AG cut its stake in Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 11.3% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 2,108,100 shares of the biotechnology company's stock after selling 267,825 shares during the period. Be

Scout Investments Inc. decreased its holdings in shares of Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 14.6% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 364,385 shares of the biotechnology company's s

Pinebridge Investments L.P. raised its holdings in Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 1,026.3% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 331,831 shares of the biotechnology company's stock after acquiring an additi

Exelixis, Inc. (NASDAQ:EXEL - Get Free Report) Director Jack L. Wyszomierski sold 8,287 shares of the firm's stock in a transaction dated Tuesday, June 4th. The shares were sold at an average price of $22.00, for a total transaction of $182,314.00. Following the completion of the transaction, the director now directly owns 349,499 shares in the company, valued at $7,688,978. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

StockNews.com cut shares of Exelixis from a "strong-buy" rating to a "buy" rating in a report on Tuesday.

Stephens Investment Management Group LLC reduced its stake in Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 2.1% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 4,106,664 shares of the biotechnology company's stock after selling

Cambridge Investment Research Advisors Inc. increased its stake in Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 1,125.7% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 165,905 shares of the biotechnolo

Franklin Resources Inc. raised its stake in shares of Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 23.6% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 434,471 shares of the biotechnology company's stock after acquiring an additional 82,9

Norges Bank acquired a new stake in Exelixis, Inc. (NASDAQ:EXEL - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm acquired 3,061,647 shares of the biotechnology company's stock, valued at approximately $73,449,000. Norges Bank owned app

Amalgamated Bank decreased its position in Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 27.3% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 168,482 shares of the biotechnology company's stock after sell